Lexaria Bioscience Corp. - SIC # 6794 - PATENT OWNERS AND LESSORS

Ticker Exchange SIC # Website Latest Ticker
LEXX Nasdaq 6794 lexariabioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lexaria Bioscience Corp.

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - May 19th, 2026 7:15 am
Lexaria Updates Progress on Human Study #7 - May 5th, 2026 7:10 am
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications - May 1st, 2026 7:25 am
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Apr 29th, 2026 7:10 am
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - Apr 23rd, 2026 7:05 am
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales - Apr 21st, 2026 7:10 am
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property - Apr 15th, 2026 7:10 am
Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely - Apr 15th, 2026 4:25 am
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval - Apr 7th, 2026 7:10 am
Lexaria to Begin New Human Clinical Study in GLP-1 - Apr 1st, 2026 7:20 am
Lexaria's Robust Patent Portfolio Continues to Grow - Mar 26th, 2026 7:20 am
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - Mar 24th, 2026 7:15 am
Lexaria Announces New R&D Plans for 2026 - Mar 4th, 2026 7:25 am
LEXX: First Quarter Results - Feb 10th, 2026 5:20 am
Lexaria Announces Positive Final Results From Human Pilot Study #5 - Feb 5th, 2026 7:15 am
Lexaria Awarded Six Additional Patents - Jan 22nd, 2026 7:20 am
Lexaria Releases Annual Letter from the CEO - Jan 12th, 2026 7:10 am
Lexaria releases additional results from Phase 1b study GLP-1-H24-4 - Dec 31st, 2025 7:25 am
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - Dec 30th, 2025 7:20 am
LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Dec 24th, 2025 2:15 am